Get started

Abbvie

ABBVIE broke below the 1D MA50. Confirmed sell opportunity.AbbVie Inc. (ABBV) has been trading within a Channel Up pattern since the November 09 2023 Low. Having made a Higher High on September 04 and been rejected at the top of the Channel Up, the price broke and closed aggressively below its 1D MA50 (blue trend-line) three days ago. That is a confirmed technical sell signal. The 1D RSI has been on Lower Highs before the actual High, very similar to the previous top on March 12 2024. That sequence, after breaking below its 1D MA50, extended aggressively towards the 1D MA200 (orange trend-line) and bottomed on the 0.618 Fibonacci retracement level. As a result, we can take a low risk sell now and target a potential contact with the 1D MA200 at $180.00. As far as buying the dip for the long-term is concerned, the most consistent buy signal has been the 1D RSI Bullish Divergence when it forms the first Higher Lows sequence after breaking below the 30.00 oversold barrier. So far that has worked 3 times almost perfectly, with the only exception the May 29 2024 bottom, which still was formed not that far away from the April 26 buy signal. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVShort
by TradingShot
2
AbbVie Faces Humira Headwinds: Stock Dips 4.76%AbbVie Inc. ( NYSE:ABBV ) struggles with declining sales volumes of its blockbuster arthritis drug, Humira. Despite a positive outlook for its newer immunology treatments, Skyrizi and Rinvoq, concerns over the impact of biosimilar competition and shifting patient preferences have cast a shadow over the pharmaceutical giant's performance, leading to a dip in its stock price. Humira Volume Erosion Worries Weigh on AbbVie AbbVie's forecast of a 32% decline in U.S. Humira sales for the second quarter has sent ripples through the market, with investors expressing apprehension over the escalating erosion of the drug's market share. The introduction of biosimilars and changes by U.S. pharmacy benefit managers have contributed to the anticipated decline, prompting AbbVie ( NYSE:ABBV ) to brace for a challenging road ahead. Navigating the Biosimilar Landscape Despite the onslaught of biosimilar competition, AbbVie ( NYSE:ABBV ) remains steadfast in its efforts to retain market dominance, emphasizing its ability to retain the majority of the Humira market. However, concerns linger as health insurer Cigna's plans to offer biosimilar alternatives without out-of-pocket payments threaten to further impact Humira's volume, adding to the company's woes. Focus on Skyrizi and Rinvoq In light of the Humira sales decline, AbbVie ( NYSE:ABBV ) has intensified its focus on promoting its newer immunology treatments, Skyrizi and Rinvoq, as key drivers of future growth. The company's raised annual profit forecast reflects confidence in the performance of these drugs, which have demonstrated strong sales in the first quarter, surpassing analyst expectations. Strategic Adjustments Amidst Uncertainty AbbVie's proactive measures to address the challenges posed by Humira's erosion underscore its commitment to resilience and adaptability in the face of market headwinds. With a revised profit forecast and robust sales performance of Skyrizi and Rinvoq, AbbVie remains poised to weather the storm and emerge stronger, reaffirming its position as a leading player in the pharmaceutical industry. Conclusion: AbbVie's outlook amidst the backdrop of Humira volume erosion reflects the dynamic nature of the pharmaceutical landscape, where innovation and adaptability are essential for long-term success. As the company continues to navigate through challenges posed by biosimilar competition and shifting market dynamics, its strategic focus on newer treatments and proactive measures will be critical in shaping its trajectory in the months ahead.
NYSE:ABBVShort
by DEXWireNews
Immunogen (NASDAQ: IMGN) Surge on News of Takeover by AbbVieAbbVie (NYSE:ABBV) announced Thursday that it will acquire Immunogen (IMGN) and its flagship cancer therapy, Elahere, in a deal worth $31.26 per share. The transaction values ImmunoGen (NASDAQ:IMGN) at a total equity value of approximately $10.1 billion and is expected to close in the middle of 2024. Elahere is considered a "first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC)." ABBV believes the deal accelerates its commercial and clinical presence in the solid tumor space. "The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify our oncology pipeline across solid tumors and hematologic malignancies," said Richard Gonzalez, chairman and chief executive officer of AbbVie. "Together, AbbVie and ImmunoGen have the potential to transform the standard of care for people living with cancer." ImmunoGen shares have rocketed 83% to over $29 per share on the news. "We see the deal as a positive for biotech as it reflects our view that quality oncology assets are of high interest to large pharma and merit a premium". Price Momentum IMGN is trading near the top of its 52-week range and above its 200-day simple moving average. What does this mean? Investors have been pushing the share price higher, and the stock still appears to have upward momentum. This is a positive sign for the stock's future value.
ILong
by DEXWireNews
ABBVIE Short term buy signal.ABBV is on a bearish 1D technical outlook (RSI = 39.987, MACD = -1.990, ADX = 42.078) but is quite possibly forming a short term bottom as the 1D RSI rebounded from an oversold level (under 30.00), while the MACD is close to forming a Bullish Cross. Every time those two conditions were fulfilled simultaneously inside the 1 year Channel Down, the price was a buy. Go long and target a similar LH trendline to early 2023 (TP = 153.00). ## If you like our free content follow our profile to get more daily ideas. ## ## Comments and likes are greatly appreciated. ##
NYSE:ABBVLong
by InvestingScope
1
ABBV AbbVie Options Ahead of EarningsIf you haven`t bought the dip on ABBV here: Then analyzing the options chain and the chart patterns of ABBV AbbVie prior to the earnings report this week, I would consider purchasing the 147usd strike price Calls with an expiration date of 2023-11-17, for a premium of approximately $3.30. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NYSE:ABBVLong
by TopgOptions
1
ABBVIE Any pull-back is a buy opportunity.AbbVie Inc. (ABBV) is having the strongest 1D candle since October 13 2022, hitting the 1D MA200 (orange trend-line) for the first time in almost three months. The long-term pattern is a Channel Down and this one is the bullish leg to a new Lower High. The 1D RSI has breached into overbought (70.00>) territory so any pull-back is a buy, even on the current levels. Our medium-term target is the 0.786 Fibonacci retracement level (158.50) similar to what happened on the December 09 2022 High. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVLong
by TradingShot
1
ABBV more probable to go down first before reaching ATHThis idea is based on Wyckoff's method for determining price objectives using the Point & Figure count of distribution ranges. We can a distribution ranges following schematic 2 for Wyckoff's distribution. If we take count the ranges separately, this yields a potential reversal zone between 118.50 and 94.50 dollar per share. Personally I am intend to buy if price reached 106.50 (mid point) All other information is on the chart. Good luck, NQDecipher
NYSE:ABBVShort
by NQunlocked
ABBV Long-term buy confirmedAbbVie Inc. (ABBV) opened today much higher than the 1D MA200 (orange trend-line), which is a strong enough buy signal on its own. Coupled however with the fact that the rebound was achieved on the Higher Lows trend-line that started way back on the COVID (March 23 2020) market bottom, it makes it an even stronger one. In fact on a 2-3 month basis, this is the most optimal buy signal an investor can have. As you see on this 1D chart, the stock had 4 Higher High touches during that period and the only time the price broke above the Channel Up was on February 16 2022 the break-out of which peaked on April 08 2022. With the help of the Fibonacci Channel levels we can see why the price stopped where it stopped. In fact we also see the important role of the median (Fib 0.5). Based on the above, we expect a new Higher high around the $180.00 price mark. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:ABBVLong
by TradingShot
1
Technical analysis of AbbVie #ABBVHey traders, My weekly trade idea. The daily price is forming a textbook Cup&Handle formation. After the consolidation in the handle phase, the price is ready to go higher. The momentum will push the price and in my opinion, it is headed to test the all-time high in the 180$ area. The Relative Strength Index broke above its trend line and is moving upward to push the price. Furthermore, when we plot different standard deviations and volume profile, it becomes clear that there is a lot of support and volume right below current price levels! I would love to hear your thoughts as well. Cheers
NYSE:ABBVLong
by RickHardyPro
3
If ABBV chooses to decline, we are ready.AbbVie - 30d expiry - We look to Sell a break of 132.58 (stop at 137.03) 133 continues to hold back the bears. 132.75 has been pivotal. Posted a Double Bottom formation. A break of the recent low at 132.74 should result in a further move lower. Our profit targets will be 121.01 and 117.01 Resistance: 154 / 157 / 160 Support: 147 / 142 / 137 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:ABBVShort
by Saxo
1
Waterfall on AbbVie. ABBVBetting on a further crash in AbbVie stock price. That huge candle preempts formal volatility switch. Fractally, hard to tell from this picture, possibly a start of a C in a WXY pattern. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Confirmation level, where relevant, is a pink dotted, finite line. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe.
NYSE:ABBVShort
by Rykin_Capital
AbbVie. Waiting for an exit from uptrendAbbVie Inc. Idea: Long Horizon: 1-2 months Target: $145 Entry range: $143-145 Stop order: $141 Technical analysis The share price has formed a short-term uptrend. If the local resistance level is broken through, there is a potential to move higher. Idea to increase the stock with the target of $145. Fundamental factor AbbVie is an American biopharmaceutical company founded in 2013 by a spinoff from Abbott Laboratories. One of the largest pharmaceutical companies in the world. Healthcare is a classic defensive sector in times of stock market turbulence. Given the high likelihood of continued serious tightening of monetary policy by the Fed, investors are shifting funds from interest-rate-dependent sectors to more stable ones. AbbVie's broadly diversified portfolio of drugs and products makes it one of the best candidates for this strategy.
NYSE:ABBVLong
by SiriusBH
AbbVie Inc, ABBV NYSE 4HNYSE:ABBV rsi in the oversold territory, which is starting to reverse to the bull side, flipped bullish on a micro timescale, falling wedge, breaking out to the upside, first target 140.75, then possible retest before 146.26. we've been in this long term downtrend channel since April 2022, I expect to break out of it, once we test 150.36 flip it as support then go for for 175.89 previous April top. fundamentals and news tend to effect this stock a lot, so with positive momentum and good news. bullish times could be ahead. Bear scenario is we test 125 before a full reset. For the current quarter, AbbVie is expected to post earnings of $3.59 per share, indicating a change of +7.8% from the year-ago quarter. The Zacks Consensus Estimate has changed -2.2% over the last 30 days. The consensus earnings estimate of $13.90 for the current fiscal year indicates a year-over-year change of +9.5%. This estimate has changed +0.2% over the last 30 days. all this is just my opinion , none of what I say should be taken as financial advice. DYOR Regards Percy
NYSE:ABBVLong
by TechnicallyBullish
ABBV ready to bounce? AbbVie Short Term We look to Buy at 138.60 (stop at 133.69) Preferred trade is to buy on dips. There is scope for mild selling at the open but losses should be limited. We therefore, prefer to fade into the dip with a tight stop in anticipation of a move back higher. Further upside is expected although we prefer to set longs at our bespoke support levels at 139.00, resulting in improved risk/reward. Our profit targets will be 152.11 and 171.00 Resistance: 146.00 / 155.00 / 172.00 Support: 139.00 / 135.00 / 126.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NYSE:ABBVLong
by Saxo
ABBV - UPDATE!I was away from TradingView for a few days, but I'm back now and continue to look at the market and look for ideas! Updating ABBV idea: Well, after the report, we teleported to shoulder level. And now several scenarios are possible: 1) Shoulder bounce 2) Shoulder breakout Which one am I more likely to go with? A shoulder breakout. But is it worth taking a position right now? I don't think it's best to be in it from the day of the report. I'm not in a position, just watching.
NYSE:ABBVShort
by Myst_Trader
2